864825-21-8

Basic information

• Product Name: (S)-benzyl 1-(4-phenyl-1H-iMidazol-2-yl)ethylcarbaMate
• Synonyms: (S)-benzyl 1-(4-phenyl-1H-iMidazol-2-yl)ethylcarbaMate;N-[(1S)-1-(5-Phenyl-1H-imidazol-2-yl)ethyl]carbamic acid phenylmethyl ester;Carbamic acid, [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester;benzyl (S)-(1-(4-phenyl-1H-imidazol-2-yl)ethyl)carbamate
• CAS NO: 864825-21-8
• Molecular Formula: C₁₉H₁₉N₃O₂
• Molecular Weight: 321.37306
• EINECS: -0
• Mol File: 864825-21-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-benzyl 1-(4-phenyl-1H-iMidazol-2-yl)ethylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl 1-(4-phenyl-1H-iMidazol-2-yl)ethylcarbaMate(864825-21-8)
• EPA Substance Registry System: (S)-benzyl 1-(4-phenyl-1H-iMidazol-2-yl)ethylcarbaMate(864825-21-8)

Safety Data

• Hazardous Substances Data: 864825-21-8(Hazardous Substances Data)

Usage

Description

(S)-Benzyl 1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate is a chemical compound that is an impurity of Eluxadoline (E508195), an orally-active drug used to treat irritable bowel syndrome.

Uses

Used in Pharmaceutical Industry:
(S)-Benzyl 1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate is used as an impurity in Eluxadoline, an orally-active drug for reducing symptoms of irritable bowel syndrome such as diarrhea and abdominal pain. Its presence in the drug may affect the efficacy and safety of the treatment.

Upstream product

• 6530-41-2 N-benzyloxycarbonyl-L-alanate de benzoylmethyle 
• 5468-37-1 2-aminoacetophenone hydrochloride 
• 1142-20-7 N-Cbz-Ala 
• 864825-19-4 benzyl (S)-(1-oxo-1-((2-oxo-2-phenylethyl)amino)propan-2-yl)carbamate 

Downstream Products

• 864825-23-0 [(S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amine 
• 864825-27-4 (2-(4-hydroxy-2,6-dimethyl-phenyl)-1-{isopropyl-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-carbamoyl}-ethyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma

Uveal melanoma is the ocular malignancy and mainly driven by oncogenic mutations of Gαq/11 proteins. Previous targeted therapy for melanoma treatment was limited to specific downstream signaling pathway, and inhibiting the "molecular switches"G proteins for melanoma treatment therapy was rarely described. We herein report the discovery of imidazopiperazine derivatives as Gαq/11 protein inhibitors. The most promising compound GQ127 showed good efficacy and safety in inositol monophosphate (IP1) assay by directly inhibiting Gαq/11 proteins. GQ127 induced uveal melanoma cells apoptosis and displayed potent antitumor activities in uveal melanoma cells viability, migration, and invasion. The effects of GQ127 on Gαq/11 signaling pathway were confirmed by analyzing the downstream effectors yes-associated protein (YAP) and extracellular signal-regulated kinase (ERK). More importantly, GQ127 significantly suppressed UM xenograft growth in mouse model without severe toxicity at the testing dose. These findings provide a lead compound that directly targets the Gαq/11 proteins for uveal melanoma treatment.

PROCESS FOR THE PREPARATION OF OPIOID MODULATORS

The present invention is directed to novel processes for the preparation of opioid modulators (agonists and antagonists) and intermediates in their synthesis. The opioid modulators are useful for the treatment and prevention of as pain and gastrointestina